Medical - Devices
Compare Stocks
4 / 10Stock Comparison
ESTA vs INMD vs AEYE vs STAA
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Software - Application
Medical - Instruments & Supplies
ESTA vs INMD vs AEYE vs STAA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Software - Application | Medical - Instruments & Supplies |
| Market Cap | $2.11B | $884M | $98M | $1.32B |
| Revenue (TTM) | $230M | $375M | $40M | $239M |
| Net Income (TTM) | $-44M | $87M | $-3M | $-80M |
| Gross Margin | 70.1% | 77.8% | 78.3% | 75.6% |
| Operating Margin | -12.4% | 21.3% | -7.9% | -33.3% |
| Forward P/E | — | 10.3x | — | 68.6x |
| Total Debt | $264M | $13M | $721K | $38M |
| Cash & Equiv. | $76M | $303M | $5M | $153M |
ESTA vs INMD vs AEYE vs STAA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Establishment Labs … (ESTA) | 100 | 364.7 | +264.7% |
| InMode Ltd. (INMD) | 100 | 95.2 | -4.8% |
| AudioEye, Inc. (AEYE) | 100 | 92.8 | -7.2% |
| STAAR Surgical Comp… (STAA) | 100 | 68.8 | -31.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ESTA vs INMD vs AEYE vs STAA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ESTA is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 27.1%, EPS growth 42.7%, 3Y rev CAGR 9.3%
- 190.0% 10Y total return vs STAA's 265.6%
- 27.1% revenue growth vs STAA's -23.7%
- +106.2% vs AEYE's -34.1%
INMD carries the broadest edge in this set and is the clearest fit for sleep-well-at-night.
- Lower volatility, beta 1.00, Low D/E 1.9%, current ratio 9.88x
- Lower P/E (10.3x vs 68.6x)
- 23.3% margin vs STAA's -33.6%
- 11.8% ROA vs STAA's -17.8%, ROIC 13.5% vs -13.2%
AEYE lags the leaders in this set but could rank higher in a more targeted comparison.
STAA is the clearest fit if your priority is income & stability and defensive.
- beta 0.49
- Beta 0.49, current ratio 4.55x
- Beta 0.49 vs AEYE's 2.18, lower leverage
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.1% revenue growth vs STAA's -23.7% | |
| Value | Lower P/E (10.3x vs 68.6x) | |
| Quality / Margins | 23.3% margin vs STAA's -33.6% | |
| Stability / Safety | Beta 0.49 vs AEYE's 2.18, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +106.2% vs AEYE's -34.1% | |
| Efficiency (ROA) | 11.8% ROA vs STAA's -17.8%, ROIC 13.5% vs -13.2% |
ESTA vs INMD vs AEYE vs STAA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ESTA vs INMD vs AEYE vs STAA — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
INMD leads in 3 of 6 categories
STAA leads 1 • ESTA leads 0 • AEYE leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
INMD leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
INMD is the larger business by revenue, generating $375M annually — 9.3x AEYE's $40M. INMD is the more profitable business, keeping 23.3% of every revenue dollar as net income compared to STAA's -33.6%. On growth, ESTA holds the edge at +44.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $230M | $375M | $40M | $239M |
| EBITDAEarnings before interest/tax | -$24M | $81M | -$504,000 | -$71M |
| Net IncomeAfter-tax profit | -$44M | $87M | -$3M | -$80M |
| Free Cash FlowCash after capex | -$42M | $91M | $2M | -$34M |
| Gross MarginGross profit ÷ Revenue | +70.1% | +77.8% | +78.3% | +75.6% |
| Operating MarginEBIT ÷ Revenue | -12.4% | +21.3% | -7.9% | -33.3% |
| Net MarginNet income ÷ Revenue | -19.1% | +23.3% | -7.6% | -33.6% |
| FCF MarginFCF ÷ Revenue | -18.3% | +24.2% | +5.5% | -14.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +44.7% | +5.3% | +7.9% | +18.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +35.7% | -30.8% | +29.0% | +47.8% |
Valuation Metrics
INMD leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $2.1B | $884M | $98M | $1.3B |
| Enterprise ValueMkt cap + debt − cash | $2.3B | $595M | $93M | $1.2B |
| Trailing P/EPrice ÷ TTM EPS | -41.73x | 9.76x | -31.44x | -16.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 10.32x | — | 68.65x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.98x | — | — |
| EV / EBITDAEnterprise value multiple | — | 6.91x | — | — |
| Price / SalesMarket cap ÷ Revenue | 9.99x | 2.39x | 2.42x | 5.51x |
| Price / BookPrice ÷ Book value/share | 90.29x | 1.34x | 20.31x | 3.84x |
| Price / FCFMarket cap ÷ FCF | — | 10.49x | — | — |
Profitability & Efficiency
INMD leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
INMD delivers a 13.3% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-2 for ESTA. INMD carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ESTA's 11.23x. On the Piotroski fundamental quality scale (0–9), ESTA scores 4/9 vs STAA's 1/9, reflecting mixed financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.3% | +13.3% | -47.8% | -23.2% |
| ROA (TTM)Return on assets | -12.7% | +11.8% | -9.5% | -17.8% |
| ROICReturn on invested capital | -14.6% | +13.5% | -42.4% | -13.2% |
| ROCEReturn on capital employed | -14.1% | +12.1% | -17.7% | -11.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 | 4 | 1 |
| Debt / EquityFinancial leverage | 11.23x | 0.02x | 0.15x | 0.11x |
| Net DebtTotal debt minus cash | $189M | -$289M | -$5M | -$115M |
| Cash & Equiv.Liquid assets | $76M | $303M | $5M | $153M |
| Total DebtShort + long-term debt | $264M | $13M | $721,000 | $38M |
| Interest CoverageEBIT ÷ Interest expense | -0.96x | — | -2.79x | — |
Total Returns (Dividends Reinvested)
Evenly matched — ESTA and AEYE and STAA each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ESTA five years ago would be worth $10,523 today (with dividends reinvested), compared to $2,394 for STAA. Over the past 12 months, ESTA leads with a +106.2% total return vs AEYE's -34.1%. The 3-year compound annual growth rate (CAGR) favors AEYE at 5.4% vs STAA's -26.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +4.3% | -5.7% | -21.0% | +13.1% |
| 1-Year ReturnPast 12 months | +106.2% | -1.9% | -34.1% | +36.7% |
| 3-Year ReturnCumulative with dividends | +6.0% | -60.1% | +17.1% | -60.5% |
| 5-Year ReturnCumulative with dividends | +5.2% | -61.5% | -57.7% | -76.1% |
| 10-Year ReturnCumulative with dividends | +190.0% | +105.6% | +96.5% | +265.6% |
| CAGR (3Y)Annualised 3-year return | +2.0% | -26.4% | +5.4% | -26.6% |
Risk & Volatility
STAA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
STAA is the less volatile stock with a 0.49 beta — it tends to amplify market swings less than AEYE's 2.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. STAA currently trades 86.6% from its 52-week high vs AEYE's 48.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.27x | 1.00x | 2.18x | 0.49x |
| 52-Week HighHighest price in past year | $83.31 | $16.74 | $16.39 | $30.81 |
| 52-Week LowLowest price in past year | $33.30 | $12.72 | $5.31 | $15.64 |
| % of 52W HighCurrent price vs 52-week peak | +86.1% | +83.4% | +48.0% | +86.6% |
| RSI (14)Momentum oscillator 0–100 | 60.4 | 46.6 | 66.5 | 66.0 |
| Avg Volume (50D)Average daily shares traded | 452K | 815K | 195K | 1.1M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ESTA as "Buy", INMD as "Hold", STAA as "Hold". Consensus price targets imply 21.8% upside for INMD (target: $17) vs -14.0% for STAA (target: $23).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | — | Hold |
| Price TargetConsensus 12-month target | $85.00 | $17.00 | — | $22.95 |
| # AnalystsCovering analysts | 14 | 11 | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +14.4% | 0.0% | +0.5% |
INMD leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). STAA leads in 1 (Risk & Volatility). 1 tied.
ESTA vs INMD vs AEYE vs STAA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ESTA or INMD or AEYE or STAA a better buy right now?
For growth investors, Establishment Labs Holdings Inc.
(ESTA) is the stronger pick with 27. 1% revenue growth year-over-year, versus -23. 7% for STAAR Surgical Company (STAA). InMode Ltd. (INMD) offers the better valuation at 9. 8x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate Establishment Labs Holdings Inc. (ESTA) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ESTA or INMD or AEYE or STAA?
On forward P/E, InMode Ltd.
is actually cheaper at 10. 3x.
03Which is the better long-term investment — ESTA or INMD or AEYE or STAA?
Over the past 5 years, Establishment Labs Holdings Inc.
(ESTA) delivered a total return of +5. 2%, compared to -76. 1% for STAAR Surgical Company (STAA). Over 10 years, the gap is even starker: STAA returned +265. 6% versus AEYE's +96. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ESTA or INMD or AEYE or STAA?
By beta (market sensitivity over 5 years), STAAR Surgical Company (STAA) is the lower-risk stock at 0.
49β versus AudioEye, Inc. 's 2. 18β — meaning AEYE is approximately 343% more volatile than STAA relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 11% for Establishment Labs Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ESTA or INMD or AEYE or STAA?
By revenue growth (latest reported year), Establishment Labs Holdings Inc.
(ESTA) is pulling ahead at 27. 1% versus -23. 7% for STAAR Surgical Company (STAA). On earnings-per-share growth, the picture is similar: Establishment Labs Holdings Inc. grew EPS 42. 7% year-over-year, compared to -295. 1% for STAAR Surgical Company. Over a 3-year CAGR, AEYE leads at 10. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ESTA or INMD or AEYE or STAA?
InMode Ltd.
(INMD) is the more profitable company, earning 25. 3% net margin versus -33. 6% for STAAR Surgical Company — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INMD leads at 23. 0% versus -19. 2% for STAA. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ESTA or INMD or AEYE or STAA more undervalued right now?
On forward earnings alone, InMode Ltd.
(INMD) trades at 10. 3x forward P/E versus 68. 6x for STAAR Surgical Company — 58. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INMD: 21. 8% to $17. 00.
08Which pays a better dividend — ESTA or INMD or AEYE or STAA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is ESTA or INMD or AEYE or STAA better for a retirement portfolio?
For long-horizon retirement investors, STAAR Surgical Company (STAA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
49), +265. 6% 10Y return). AudioEye, Inc. (AEYE) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (STAA: +265. 6%, AEYE: +96. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ESTA and INMD and AEYE and STAA?
These companies operate in different sectors (ESTA (Healthcare) and INMD (Healthcare) and AEYE (Technology) and STAA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ESTA is a small-cap high-growth stock; INMD is a small-cap deep-value stock; AEYE is a small-cap quality compounder stock; STAA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.